Roger Song
Stock Analyst at Jefferies
(3.91)
# 661
Out of 5,042 analysts
52
Total ratings
47.62%
Success rate
13.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GYRE Gyre Therapeutics | Initiates: Buy | $16 | $8.17 | +95.84% | 1 | Oct 10, 2025 | |
| TRML Tourmaline Bio | Downgrades: Hold | $64 → $48 | $47.98 | -1.00% | 3 | Sep 9, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $432 → $564 | $418.58 | +34.74% | 1 | Sep 2, 2025 | |
| BMEA Biomea Fusion | Initiates: Buy | $5 | $1.46 | +242.47% | 1 | Aug 28, 2025 | |
| ATYR aTyr Pharma | Maintains: Buy | $9 → $17 | $0.97 | +1,660.56% | 2 | Aug 22, 2025 | |
| MBX MBX Biosciences | Assumes: Buy | $36 | $17.00 | +111.76% | 1 | Aug 15, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Hold | $3 → $1.5 | $1.61 | -6.83% | 1 | Aug 5, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $54 | $38.93 | +38.71% | 3 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Buy | $31 → $6 | $8.80 | -31.82% | 2 | Jul 22, 2025 | |
| CVAC CureVac | Downgrades: Hold | $7 → $5 | $5.36 | -6.72% | 1 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $60.10 | -50.08% | 11 | Apr 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $3.03 | +98.02% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $5.59 | +25.22% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $245 | $186.13 | +31.63% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $7.13 | +264.66% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $42 → $7 | $7.60 | -7.89% | 2 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $9.70 | +188.66% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $2.15 | +225.58% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $85.63 | +3.94% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $8.52 | +193.43% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $11.09 | +269.70% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $23.90 | +46.47% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $42.24 | +205.40% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2.5 → $8 | $3.26 | +145.40% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $93.39 | +3.87% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $34.42 | +219.58% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $3.95 | +786.08% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.62 | +455.56% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $7.35 | +8.84% | 2 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.05 | +1,900.00% | 1 | Sep 2, 2020 |
Gyre Therapeutics
Oct 10, 2025
Initiates: Buy
Price Target: $16
Current: $8.17
Upside: +95.84%
Tourmaline Bio
Sep 9, 2025
Downgrades: Hold
Price Target: $64 → $48
Current: $47.98
Upside: -1.00%
United Therapeutics
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $418.58
Upside: +34.74%
Biomea Fusion
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $1.46
Upside: +242.47%
aTyr Pharma
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $0.97
Upside: +1,660.56%
MBX Biosciences
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $17.00
Upside: +111.76%
LAVA Therapeutics
Aug 5, 2025
Downgrades: Hold
Price Target: $3 → $1.5
Current: $1.61
Upside: -6.83%
Kiniksa Pharmaceuticals International,
Jul 29, 2025
Maintains: Buy
Price Target: $45 → $54
Current: $38.93
Upside: +38.71%
Replimune Group
Jul 22, 2025
Maintains: Buy
Price Target: $31 → $6
Current: $8.80
Upside: -31.82%
CureVac
Jun 13, 2025
Downgrades: Hold
Price Target: $7 → $5
Current: $5.36
Upside: -6.72%
Apr 11, 2025
Upgrades: Buy
Price Target: $15 → $30
Current: $60.10
Upside: -50.08%
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $3.03
Upside: +98.02%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $5.59
Upside: +25.22%
Mar 5, 2025
Initiates: Buy
Price Target: $245
Current: $186.13
Upside: +31.63%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $7.13
Upside: +264.66%
Dec 9, 2024
Downgrades: Hold
Price Target: $42 → $7
Current: $7.60
Upside: -7.89%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $9.70
Upside: +188.66%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $2.15
Upside: +225.58%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $85.63
Upside: +3.94%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $8.52
Upside: +193.43%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $11.09
Upside: +269.70%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $23.90
Upside: +46.47%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $42.24
Upside: +205.40%
May 6, 2024
Upgrades: Buy
Price Target: $2.5 → $8
Current: $3.26
Upside: +145.40%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $93.39
Upside: +3.87%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $34.42
Upside: +219.58%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $3.95
Upside: +786.08%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $1.62
Upside: +455.56%
Dec 1, 2021
Initiates: Buy
Price Target: $8
Current: $7.35
Upside: +8.84%
Sep 2, 2020
Initiates: Buy
Price Target: $21
Current: $1.05
Upside: +1,900.00%